• New Hope for Patients as Landmark Study Confirms Efficacy of Severe Eczema Treatment

HONG KONG, Sept. 10, 2026 (GLOBE NEWSWIRE) — Scientist Home Future Health LTD (OTCID: SHFH) (Scientist home or ‘The Company’) is pleased to announce Researchers at Scientist Home have announced promising results from a landmark clinical trial, showing a significant reduction in the severity and duration of symptoms for patients suffering from Severe Eczema. The findings in the significant reduction of symptoms mark a potential turning point in the management of this challenging condition.

“For too long, patients have struggled with the relentless burden of their symptoms, often trying treatments with limited success or undesirable side effects, highlighting the urgent need for a new treatment option,” said Dr. UL AIN Qurat, the study’s lead investigator, Medical Doctor, registered in Pakistan and a Senior Nutritionist & Wellness Consultant at Scientist Home Future Health Hong Kong. “Our goal with this trial was to evaluate a more targeted approach that could offer meaningful and sustained relief.”

Eczema Mechanism: An immune mediated inflammatory disease

Eczema happens when the body’s defense system overreacts to harmless things like dust, pollen, pets or allergen and the “brakes” of the immune system do not work well, irrespective of any age. In people with eczema, allergy antibodies such as IgE and IgG are often higher, which makes mast cells and other immune cells in the skin release chemicals that cause redness and intense itching. Protective IgA, which normally helps block germs and allergens at the skin and mucosa, may be too low or not work properly, so more triggers get into the body and keep the allergy reaction going. Complement proteins like C3 and C4 act like chemical alarms: once switched on by these antibody reactions, they attract even more inflammatory cells into the skin and worsen swelling and irritation. Regulatory T cells (Treg) are the immune “controllers” that should calm these reactions, but when they are too few or not effective, the inflammation is not switched off, so eczema flares become frequent and long‑lasting.

The immune pathogenesis of eczema (atopic dermatitis) is primarily driven by a Type 2 Helper T cell (Th2) inflammatory response, a core mechanism it shares with a spectrum of other diseases, which can be categorized into the sequential “atopic march” conditions—including food allergy, allergic rhinitis, asthma, and eosinophilic esophagitis—that arise from a similar genetic and immunological predisposition, as well as other inflammatory disorders like prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria, all of which involve overactivation of the Th2 immune axis and its key cytokines (such as IL-4, IL-13, and IL-31), though each condition also possesses distinct clinical features and may involve additional complex pathophysiological processes. These conditions share a common genetic and immune-system-related predisposition.

With Scientist Home Future Health nutrition therapy, this dysregulated immune response is modulated with supplements having naturally derived ingredients to ensure no side effects and the skin barrier is restored with scientifically proven mechanism.

The SHFH supplement breakthrough transmembrane transport technology (TTT) dramatically enhances intestinal absorption of therapeutic compounds, allowing a much higher percentage of active ingredients to reach the bloodstream efficiently. By overcoming the natural barriers of the intestinal epithelium, it achieves superior bioavailability compared to traditional formulations. As a result, patients often experience rapid and noticeable improvements in symptoms (such as reduced inflammation, itching, sleeping or overall management of the condition like eczema) within just 2–4 days of use, as therapeutic or supportive levels are delivered to target tissues far more quickly and effectively than with standard products.

SHFH Expands Strategic Investment in Innovative Eczema Therapeutic Technology

Eczema remains a significant global health concern, impacting people across all age groups—from infants and children to adults and the elderly. With strong initial clinical outcomes, the first phase of this advanced eczema treatment project has demonstrated promising efficacy and safety.

Building on this success, SHFH has intention to acquire a 5% equity stake in the project, and we may acquire further equity stake when the project reaches other milestones.

As the project progresses into its second phase, which focuses on in-depth immunological analysis, SHFH retains the option to increase its investment by an additional 10%, contingent upon the achievement of significant scientific and clinical milestones.

Expecting the successful completion of the third phase—single arm and unblinded clinical trial in immunology—SHFH plans to further expand its stake by subscribing for an additional 36% of the equity. This investment will reflect the advanced technological and proprietary formula assets of the project.

This strategic investment underscores SHFH’s commitment to advancing innovative dermatological solutions and strengthening its leadership in immunology-driven therapies.

Building the Future of Eczema Therapy: Phased Alliances with Leading Global Partners

“As CEO, I want to be clear: we are deliberately advancing through phased stages—systematically engaging leading research institutes, clinical partners, and key stakeholders across multiple countries to build meaningful collaborations. In each phase, our focus will be on exploring joint clinical trials, rigorously evaluating complementary technologies, and negotiating robust R&D partnerships. Where the strategic fit is strong, we will forge alliances with world-class manufacturing partners to scale the most promising modalities efficiently. This thoughtful, relationship-driven approach is how we ensure the highest standards of clinical validation, seamless technology integration, and the operational scale needed to turn our scientific breakthroughs into widely accessible, life-changing treatments for patients around the world,” Sir CHAN stated.

About:
Scientist Home Future Health Limited a leading natural supplement medical center and community health provider dedicated to innovative patient care, groundbreaking research, and community education. We are committed to improving the health and well-being of the people of Hong Kong, China, Malaysia, Singapore, USA and beyond.

Disclaimer: This article summarizes the findings of a specific clinical trial. The treatment discussed may not be suitable for all patients. Always consult with a qualified healthcare professional to determine the best course of treatment for your individual health needs.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to Scientist Home Future Health Limited’s expectations regarding its initial investment, clinical and scientific milestones, and potential future equity subscriptions, and are based on current beliefs and expectations. Actual results could differ due to risks including the timing and outcome of clinical trials, regulatory approvals, achieving scientific milestones, and competition and intellectual property issues. Scientist Home Future Health Limited is not obligated to update these statements publicly unless required by law.

Media Contact:
Name: CHAN Siu Hung
Title: Founder & CEO
Email: info@shfh.ai 
Phone Number: (+852) 5702 3067

Investor Contact:
Andrew Barwicki
andrew@barwicki.com / 516-662-9461


Media gallery

About The Author
Scientist Home Future Health Limited